Artificial Intelligence (AI) has the potential to speed up the time to bring a vaccine to market by accelerating the process of human trials.
Valneva SE, a specialty vaccine company, and Instituto Butantan, producer of immunobiologic products is preparing to start Phase 3 clinical studies of a single-shot chikungunya vaccine, VLA1553, in the United States later this year.
The Phase 2b/3 study, named HVTN 702 or Uhambo, began in 2016 and was taking place in South Africa. The study was canceled because independent data and safety monitoring board (DSMB) found during an interim review that the regimen did not prevent HIV. The board did not express any concern regarding participant safety.
Better understanding of the options for trial design is needed in advance of outbreaks.